Background: Myocardial infarction (MI) with non-obstructive coronary arteries (MINOCA) is a recently recog nized condition where biomarkers and prognosis are less well studied than in MI with obstructive coronary ar tery disease (MI-CAD). We therefore aimed to investigate the one-year prognostic value of high-sensitivity cardiac troponin T (hs-cTnT) levels in MINOCA in comparison to MI-CAD. Methods: In this registry-based cohort study, we used data from patients with a discharge diagnosis of MI, admit ted between 2009 and 2013 to Swedish hospitals using the hs-cTnT assay. Only patients without previously known coronary artery disease were considered. Patients with and without coronary stenosis N50% were regarded to have MI-CAD and MINOCA, respectively. Assessed outcomes included all-cause mortality, cardiovas cular (CV) mortality and major CV events (MACE), defined as the composite of CV death or admissions for non fatal MI, heart failure (HF) or ischemic stroke. Results: The study cohort consisted of 1639 MINOCA and 17,304 MI-CAD patients. In adjusted analyses, hs-cTnT (ln) in MINOCA patients predicted all-cause mortality (HR 1.32 [95% CI 1.11-1.56]), CV mortality (HR 2.11 [95% CI 1.51-2.96]) and MACE (HR 1.44 [95% CI 1.20-1.72]). Hs-cTnT (ln) also predicted readmissions for HF (HR 1.51 [95% CI 1.51-2.96]) but not non-fatal MI or stroke. Interaction analyses suggested that hs-cTnT (ln) was at least as prognostic in patients with MINOCA compared to MI-CAD. Conclusions: Hs-cTnT levels in MINOCA patients are strong and independent predictors of adverse outcome. Con sideration of hs-cTnT levels is important for risk assessment of MINOCA patients.
Since DeWood et al showed that N90% of myocardial infarction (MI) patients had evidence of obstructive coronary artery disease (CAD) on coronary angiography, 1,2 treatment of these obstructions has been a cornerstone of the management of patients with MI. This has led to a substantial improvement in survival and other outcomes for these patients. 3, 4 However, around 1 in 10 MI patients (ranging from 1% to 13%) [5] [6] [7] present with normal or near-normal coronary arteries, so called myocardial infarction with non-obstructive coronary arteries (MINOCA). 8 MINOCA is an exclusion diagnosis and may be the result of various etiologies including plaque disruption, spasm, thromboem bolism, dissection, microvascular dysfunction and ischemic myocardial injury due to oxygen supply/demand mismatch. [9] [10] [11] [12] MINOCA is thus a heterogeneous disease state and the pathophysiological mechanisms
The prognosis of MINOCA patients is not as benign as previously assumed 14 : a recent meta-analysis concludes a one-year mortality rate of 4.7%. 11 Even though studies have descriptively reported cardiac tro ponin (cTn) levels in MINOCA, 5, [15] [16] [17] [18] the prognostic value of cTn in MINOCA, including comparisons with MI patients with obstructive CAD (MI-CAD), has not previously been assessed to the best of our knowledge. Therefore, the aim of this study was to determine the prog nostic value of cardiac troponin T (cTnT) in patients with MINOCA in comparison to those with MI-CAD.
Materials and methods

Study cohort
This registry-based study is part of the TOTAL-AMI (Tailoring Of Treatment in All comers with Acute Myocardial Infarction) project. TOTAL-AMI uses data from Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated Ac cording to Recommended Therapies (SWEDEHEART) quality registry, both of which have previously been described. 19 The study cohort is based on 63,946 patients admitted between 2009 and 2013 to hospitals, evaluated using the high-sensitivity (hs) cTnT assay (Elecsys® Troponin T high-sensitivity assay, Roche Diagnos tics, Basel, Switzerland), with 14 ng/L as the diagnostic cut-off. 20 We considered the highest hs-cTnT level measured during the hospitaliza tion, which is documented in SWEDEHEART. Only first-time admissions during the study period were counted. To reduce the potential bias of systematic reporting errors, patients were excluded from this analysis if hs-cTnT results had been obtained less than one week after the imple mentation of the hs-cTnT assay at each respective hospital or if several cTn assays had been used in parallel. Furthermore, patients with previ ous MI, percutaneous coronary intervention (PCI) or coronary artery by pass grafting (CABG) were excluded. Of the remaining patients, we se lected those who had been discharged with a diagnosis of MI (Interna tional Classification of Diseases, 10th revision, Clinical Modification [ICD 10-CM] code I21) and who had undergone coronary angiography. To fulfill the study criteria for MINOCA, patients were required to have normal or near-normal coronary arteries (b50% stenosis) and not to have undergone PCI during the hospitalization. 8, 9 MI patients with ≥50% coronary stenosis were regarded having MI-CAD. After exclusions, a total of 1639 MINOCA and 17,304 MI-CAD patients remained for the analyses (Figure 1 ).
Assessed outcomes
The data in the SWEDEHEART registry were linked to the data from the mandatory National Inpatient Registry (hospitalization dates and discharge diagnoses coded according to ICD-10-CM) and the National Cause of Death Registry held by the Swedish Board of Health and Welfare. The assessed outcomes included all-cause mor tality, cardiovascular (CV) mortality (all primary causes of death di agnosed with ICD-10-CM codes I00-I99), readmission for non-fatal MI (ICD-10-CM code I21), admission for heart failure (HF) (ICD-10 CM code I50) and ischemic stroke (ICD-10-CM code I63) as primary diagnosis within one year from the index admission. In addition, we assessed major CV events (MACE), defined as the composite of CV death, readmission for non-fatal MI and admission for HF or is chemic stroke, whatever occurred first. During the first 30 days it is not possible to separate a new MI from the index MI in the National Inpatient Registry. Therefore, only non-fatal MI occurring 30 days after the index hospitalization were counted.
According to Swedish law, all patients registered in SWEDEHEART have to be informed about the registration and the right to opt out. All data had been made anonymous before the statistical analyses were performed. The study was conducted according to the principles of the Declaration of Helsinki and had been approved by the Regional Ethical Review Board in Stockholm (2012/60-31/2).
The TOTAL-AMI project has received funding from the Swedish Foundation for Strategic Research, which had no role in the design of Patients with missing data were excluded from the analyses. Bold P values indicate statistical significance. CV, cardiovascular; ECG, electrocardiography; eGFR, estimated glomerular filtration rate; HF, heart failure; hs-cTnT, high-sensitivity cardiac troponin T; LVEF, left ventricular ejection frac tion; MACE, major cardiovascular events; MI, myocardial infarction; MI-CAD, myocardial infarction with obstructive coronary artery disease; MINOCA, myocardial infarction with non-ob structive coronary arteries; RAAS, renin-angiotensin-aldosterone system. ⁎ Available data: n = 1401 for MINOCA and n = 14,857 for MI-CAD.
study, collection and interpretation of the data, preparation of the man uscript or decision to submit it for publication. The authors are solely re sponsible for the design and conduct of this study, all study analyses, the drafting and editing of the manuscript, and its final contents.
Statistical analysis
Following assessment using the Kolmogorov-Smirnov test, all con tinuous variables had skewed distributions and are thus, reported as medians with 25th and 75th percentiles. The Mann-Whitney U test was used for between-group comparisons. Categorical variables are expressed as frequencies and percentages with differences being ana lyzed with the chi-squared test.
Cox regression analysis was used to investigate the associations of hs-cTnT with adverse outcome after having checked the proportional hazard assumptions by computing log[-log(event)]plots. Models were adjusted for established cardiovascular risk factors captured by the SWEDEHEART registry: age, sex, current smoking, hypertension, diabetes mellitus, previous HF, previous stroke, ST-segment changes and estimated glomerular filtration rate (eGFR). Also, adjustment was made for year of admittance and hospital as a random effect in a mixed model, and in-hospital coronary revascularization (patients with MI-CAD only). In sensitivity analyses, additional adjustment was made for discharge medications with antiplatelets, β-blockers, reninangiotensin-aldosterone system (RAAS) inhibitors and statins, or the left-ventricular ejection fraction (LVEF). For comparative analyses be tween groups defined by the type of MI (MINOCA vs MI-CAD), age, sex, LVEF, prevalent diabetes mellitus, eGFR and ST-elevation upon ad mission, interaction terms were added to the fully adjusted models. We also computed a full-adjusted spline plot to illustrate the association of hs-cTnT levels with MACE. Continuous variables were ln-transformed in all models to achieve a normal distribution. In addition, the KaplanMeier method and the corresponding log-rank test were used to study cumulative one-year event rates between hs-cTnT quartile groups.
In all tests, a 2-sided P b .05 was considered significant. The software packages SPSS 24.0 (SPSS Inc, Chicago, Illinois, USA) and R 3.2.2 (R Foun dation for Statistical Computing, Vienna, Austria) were used for the sta tistical analyses.
Results
Clinical characteristics, hs-cTnT levels and outcomes
Clinical characteristics, medications on admission and discharge, hs cTnT levels and outcomes of the 1639 MINOCA and 17,304 MI-CAD pa tients are shown in Table I . MINOCA patients were more often females. CV risk factors were more prevalent among MI-CAD patients, with the exception of higher prevalence of hyperlipidemia in MINOCA, and no 
Prognostic importance of hs-cTnT levels
In Figure 2A -C, hs-cTnT levels in MINOCA and MI-CAD patients with and without events are shown. Hs-cTnT levels in both groups were sig nificantly higher for patients with compared to without events for CV mortality and MACE, but not all-cause mortality.
The cumulative one-year event rates regarding all-cause mortality, CV mortality and MACE in MINOCA patients according to hs-cTnT quar tiles are shown in Figure 3A -C. The results indicate that patients belong ing to the highest hs-cTnT quartile (≥467 ng/L) had a markedly poorer prognosis regarding CV mortality and MACE compared to patients in the three lower quartiles. However, there were no differences in out come for the hs-cTnT quartiles for all-cause mortality. Table II shows the adjusted hazard ratios (HR) for hs-cTnT regarding the assessed outcomes for both patients with MINOCA and MI-CAD. The multivariable-adjusted HR of ln-transformed hs-cTnT levels regarding MACE was 1.44 (95% confidence interval [CI] 1.20-1.72) in MINOCA pa tients. The Supplemental Figure displays the multivariable-adjusted spline plot, indicating an increase in the risk of MACE along with higher hs-cTnT levels with an inflection point in the curve at a level around 500 ng/L. The prognostic value of hs-cTnT regarding MACE was mainly driven by its associations with CV mortality (HR 2.11 [95% CI 1.51 2.96]) and admission for HF (HR 1.51 [1.14-2.00]). Hs-cTnT was inde pendently predictive in patients with MI-CAD for MACE, all-cause mor tality, CV mortality, hospitalization for HF and stroke. Interaction analyses of the associations of hs-cTnT (ln) with the type of MI (MINOCA vs MI-CAD) on the risk of adverse outcome indicated that hs-cTnT (ln) was similarly predictive in both MI types apart from CV mortality, for which a stronger association in MINOCA patients emerged. In order to further explore the prognostic implications of hs cTnT levels in MINOCA, a set of sensitivity analyses was performed. Adding information on discharge medications with antiplatelets, β All analyses are adjusted for hospital, admittance year, age, sex, current smoking, hypertension, diabetes mellitus, previous heart failure, prior stroke, ST-segment changes on admittance ECG, eGFR and in-hospital revascularization, if appropriate. CI, confidence interval; CV, cardiovascular; ECG, electrocardiography; eGFR, estimated glomerular filtration rate; HF, heart failure; HR, hazard ratio; hs-cTnT, high-sensitivity cardiac tro ponin T; MACE, major cardiovascular events; MI, myocardial infarction; MI-CAD, myocardial infarction with obstructive coronary artery disease; MINOCA, myocardial infarction with nonobstructive coronary arteries.
⁎ P values refer to the interaction terms of MINOCA vs MI-CAD on the association of hs-cTnT (ln) with outcomes. Bold P values indicate statistical significance. All analyses are adjusted for hospital, admittance year, age, sex, current smoking, hyper tension, diabetes mellitus, previous heart failure, prior stroke, ST-segment changes on ad mittance ECG and eGFR, if appropriate. CI, confidence interval; ECG, electrocardiography; eGFR, estimated glomerular filtration rate; HR, hazard ratio; hs-cTnT, high-sensitivity cardiac troponin T; LVEF, left ventricular ejection fraction; MACE, major cardiovascular events; MINOCA, myocardial infarction with non-obstructedive coronary arteries. ⁎ P values refer to the interaction terms of sex, age ≤ or N68 years, LVEF ≥ or b0.50, di abetes mellitus and eGFR ≥ or b60 mL/min/1.73 m blockers, RAAS inhibitors and statins as covariates to the fully adjusted Cox model did not alter the association of hs-cTnT (ln) with MACE (HR 1.43 [95% CI 1.20-1.71]). When the LVEF was considered as catego rized variable (see Table I ) in the fully adjusted model, it emerged as an independent predictor of MACE (HR 1.56 [95% CI 1.21-2.02]) while the prognostic value of hs-cTnT (ln) was slightly attenuated but remained independent (HR 1.26 [95% CI 1.03-1.56]). Table III presents data on the prognostic value of hs-cTnT levels in MINOCA subgroups defined by sex, age, LVEF, prevalent diabetes mellitus, eGFR and ST-elevation upon admission. As indicated by the non-significant interaction terms, hs-cTnT levels exhibited similar prog nostic value in all subgroups.
Discussion
In this registry-based study investigating a large cohort of MINOCA patients, we could for the first time demonstrate that hs-cTnT levels are important prognostic markers in MINOCA patients. Higher hs-cTnT levels independently predicted adverse outcome and were at least as prognostic as in MI-CAD patients.
Hs-cTnT levels in patients with MINOCA and MI-CAD
When comparing MINOCA with MI-CAD patients, hs-cTnT levels were overall higher in the latter group. Previous small studies have yielded conflicting results in this regard. 15, 16 However, it is reason able to assume that MI-CAD patients have larger release of hs-cTnT from the myocardium than MINOCA patients, since the cause of MI CAD is an instant total or subtotal blockage of a major coronary artery 1,2 resulting in substantial injury to the affected myocardial area, whereas this is not the case in MINOCA. 9, 17 Still, our results em phasize that hs-cTnT levels carry important and independent infor mation in MINOCA.
Prognostic importance of hs-cTnT in MINOCA patients
The hs-cTnT levels were independently predictive of adverse out comes in the MINOCA patients, similarly as in MI-CAD patients. The prognostic impact of hs-cTnT levels in the MINOCA patients was robust and mainly driven by their association with CV mortality and admission for HF. MINOCA patients having hs-cTnT levels in the highest quartile (≥467 ng/L) had a particularly high rate of MACE.
Notably, hs-cTnT levels demonstrated a stronger prognostic value for CV mortality in MINOCA compared to MI-CAD despite higher hs-cTnT levels in the latter group. Unfortunately, the data collected in SWEDEHEART precludes an in-depth investigation of possible disease mechanisms explaining these discrepant findings. It is important to recognize MINOCA rather as a working diagnosis than a term characterizing a specific disease state. MINOCA may be the result of various etiologies. 9, 18 Data on optimal clinical management in MINOCA however, are lacking although position papers exist. 9, 12 The importance of MINOCA has been emphasized in the recently published European guidelines on the management of ST-elevation MI. 21 Our results indicate a need for more optimized cardioprotective pharmacotherapies in MINOCA patients. For example, only 66.0% of all MINOCA patients were discharged with RAAS inhibitors (compared to 82.8% of patients with MI-CAD), drugs for which beneficial effects in MINOCA recently were demonstrated. 22 This undertreatment might have contributed to more adverse remodeling along with higher hs cTnT levels, leading to poorer outcome in MINOCA. Adding to this no tion is the fact that hs-cTnT levels yielded similar prognostic value re garding HF requiring hospitalization in both patients with MINOCA and MI-CAD.
Prognostic importance of hs-cTnT in subgroups with MINOCA
Hs-cTnT levels were similarly prognostic in subgroups defined by age, LVEF, prevalent diabetes mellitus, eGFR and ST-elevation upon ad mission. Interestingly, hs-cTnT levels exhibited also similar prognostic value in men and women with MINOCA. The pathophysiology of CAD is known to differ between the sexes with women more often having mi crovascular and endothelial dysfunction and/or diffuse coronary athero sclerosis than men. 23 This is reflected by the overrepresentation of women among MINOCA patients in our cohort, similar as described by others. 15, 16 Nonetheless, given the non-significant interaction of sex on the association of hs-cTnT with outcome, we conclude that the prog nostic value of hs-cTnT levels does not differ between men and women in MINOCA.
Strengths and limitations
The main strength of our analysis is the large sample size with 1639 MINOCA patients who had been assessed using the same hs-cTn assay. Totally, 8.7% of all MI patients had MINOCA, which is in line with previ ous reports of prevalence. [5] [6] [7] MINOCA patients in our material had a one-year all-cause mortality of 4.2%, corresponding to the 4.7% found in a meta-analysis of eight studies 11 and the 5.2% found in MINOCA pa tients without ST-elevation from the ACUITY trial. 24 This indicates that our cohort is representative for the MINOCA population in general. Our study has also limitations that need to be considered. Although all hospitals participating in SWEDEHEART are regularly monitored, the data cannot be of the same quality as in a prospective observational study. However, a monitor annually evaluates the correctness of the data entered into the registry, and the agreement with the medical re cords is around 96%. 25 Only the highest hs-cTnT level measured during hospitalization is registered in SWEDEHEART. These values might have been influenced by variations in the blood sampling strategies between the hospitals and may not reflect true peak levels. However, this probably leads to an underestimation rather than an overestimation of the association be tween hs-cTnT value and outcome.
We cannot exclude erroneous diagnosis of MI in some cases, as the diagnoses were set locally by the treating physicians and no central ad judication of the diagnoses was performed. However, in Sweden the di agnoses of MI as well as stroke and HF have been shown to have high validity. [26] [27] [28] The data available in SWEDEHEART do not permit separation of the patients into those without angiographic signs of any atherosclerosis and those with some signs of atherosclerosis but no stenosis of ≥50%. Studies have indicated that these subgroups constitute around 50% each of the MINOCA population. 29 Moreover, coronary angiographies were evaluated locally at each hospital and not at a core laboratory. The diagnosis of MINOCA was not verified by a review of hospital re cords. Instead, we defined MINOCA using the clinical information pro vided in SWEDEHEART acknowledging the limitations related to this approach. We lack information on the results of examinations per formed after the hospitalization period. Accordingly, some patients regarded having MINOCA may have subsequently been diagnosed with myocarditis on the basis of cardiac magnetic resonance imaging performed after hospital discharge. There might also have been some cases of takotsubo syndrome in the cohort, especially during the first years of the study period when the awareness of this syndrome was limited. In the light of these considerations, we cannot exclude the pos sibility that the prognostic importance of hs-cTnT levels varies accord ing to the underlying etiology, an issue that we could not investigate in the present study.
Conclusions
In this registry-based study, we for the first time demonstrated that hs-cTnT levels are important prognostic markers in MINOCA patients. Higher hs-cTnT levels independently predicted various outcomes, in particular CV mortality and readmission for HF. Hs-cTnT levels were at least as prognostic as in MI-CAD patients. Our data further stress the im portance of considering the hs-cTnT levels in MINOCA patients.
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